Join
Live feed
·
PRReleasevia Quantisnow
SpringWorks Therapeutics Inc. logo

SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
SWTX· SpringWorks Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SWTX (SpringWorks Therapeutics Inc.) and more on Quantisnow.